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Abstract
Objectives: A recent genome wide association study (GWAS) by LeMaire et al. found that two single nucleotide
polymorphisms (SNPs), rs2118181 and rs10519177 in the FBN-1 gene (encoding Fibrillin-1), were associated with thoracic
aortic dissection (TAD), non-dissecting thoracic aortic aneurysm (TAA), and thoracic aortic aneurysm or dissection (TAAD);
the largest effect was observed for the association of rs2118181 with TAD. We investigated whether rs2118181 and
rs10519177 were associated with TAD, TAA, and TAAD in the Yale study.
Methods: The genotypes of rs2118181 and rs10519177 were determined for participants in the Yale study: 637 TAAD cases
(140 TAD, 497 TAA) and 275 controls from the United States, Hungary, and Greece. The association of the genotypes with
TAD, TAA and TAAD were assessed using logistic regression models adjusted for sex, age, study center and hypertension.
Results and Conclusions: In the Yale study, rs2118181 was associated with TAD: compared with non-carriers, carriers of the
risk allele had an unadjusted odds ratio for TAD of 1.80 (95% CI 1.15–2.80) and they had odds ratio for TAD of 1.87 (95% CI
1.09–3.20) after adjusting for sex, age, study center and hypertension. We did not find significant differences in aortic size, a
potential confounder for TAD, between rs2118181 risk variant carriers and non-carriers: mean aortic size was 5.56 (95% CI:
5.37–5.73) for risk variant carriers (CC+CT) and was 5.48 (95% CI: 5.36–5.61) for noncarriers (TT) (p = 0.56). rs2118181 was not
associated with TAA or TAAD. rs10519177 was not associated with TAD, TAA, or TAAD in the Yale study. Thus, the Yale study
provided further support for the association of the FBN-1 rs2118181SNP with TAD.
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Introduction
Thoracic aortic dissection (TAD), without surgical treatment, is
an event that is frequently fatal [1]. The related condition of
thoracic aortic aneurysm (TAA) is an important risk factor for
TAD [2]. TAA develop largely asymptomatically with most
patients feeling no pain or other symptoms until rupture or
dissection occurs [3]. Although non-dissecting TAA patients who
have undergone appropriate elective surgical treatment have a
near-normal prognosis [4–6], and despite progress in predicting
the risk of TAD in patients with established TAA based on aortic
size criteria, there is a need for improvement in the assessment of
risk for TAD, to better guide surgical decision making [7]. This is
especially true because acute aortic dissection may occur without
substantial aorta enlargement. Aortic dissection is overlooked
initially in up to 40% of cases, and the mortality rate for untreated
dissection approaches 1% per hour during the first 48 hours [1].
While radiographic diagnosis by ECHO or CT scan is highly
accurate, it is not considered appropriate or cost-effective to screen
the general population radiographically [8]. Therefore, better
identification and risk assessment for TAD and TAA are essential
goals. Genetic polymorphisms, in conjunction with traditional risk
factors, may pinpoint individuals at greater risk for TAD or
identify non-dissecting TAA better than traditional risk factors
alone [9–13]. This is especially important for those patients at high
risk for TAD who cannot be identified by aortic size alone. Thus,
genetic polymorphisms have the potential to improve clinical care
and reduce TAD and TAA related death [9].
A recent genome wide association study (GWAS) found that two
single nucleotide polymorphisms (SNPs, rs2118181 and
rs10519177) in the FBN-1 gene were associated with TAD,
TAA, and thoracic aortic aneurysm or dissection (TAAD). The
largest effect was observed for the association of rs2118181 with
TAD [9,14]. FBN-1 gene encodes for Fibrillin-1, an extracellular
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matrix protein, which is an essential component of the elastic fibers
in the aortic wall [10]. Interestingly, heterozygosity for rare
mutations in the same FBN-1 gene causes Marfan syndrome, an
autosomal dominant disorder in which patients present with
TAAD in addition to ocular and skeletal phenotypes [15].
Therefore, we investigated whether rs2118181 and rs10519177
in the FBN-1 were also associated with TAD, TAA, and TAAD in
a large group of patients studied at Yale University.
Materials and Methods
Study Subjects
Study subjects included 140 thoracic aortic dissection cases, 497
non-dissecting thoracic aortic aneurysm cases, and 275 disease-
free controls collected in the U.S. (Yale University), Hungary
(Semmelweis University), and Greece (Athens Medical Center and
Evangelismos Hospital). Controls (n = 275) included randomly
selected unaffected individuals from Greek and Hungarian study
centers who generally shared the same ethnic background,
geographic location, and environmental milieu (n = 206) and
unaffected spouses of patients with TAAD collected at Yale
University (n = 69) who generally shared the same ethnic
background, geographic location, and environmental milieu.
The physicians caring for the patients verified the aneurysm
and/or dissection phenotype from their own radiographic and
surgical records, and provided the demographic and clinical data
on the patients and controls.
The clinical characteristics of cases and controls are presented
in Table 1. All subjects provided written informed consent to
participate in the study; the study and informed consent procedure
were approved by institutional review boards of the participating
centers: the Yale University Human Investigation Committee, the
Semmelweis University (Budapest, Hungary) Institutional Review
Board, the Athens Hospital Center (Athens, Greece) Institutional
Review Board and the Evangelismos General Hospital (Athens,
Greece) Institutional Review Board.
Table 1. Characteristics of Dissection, Non-dissecting Aneurysm Cases, and Controls.
Characteristics Dissection (n =140)
Non-dissecting
aneurysm (n=497) Control (n =275) p Value* p Value{
Age, yrs 63613.1 64613.8 57615.2 0.001 ,0.0001
Male, n (%) 85 (60.7) 344(69.2) 107(39.2) ,0.0001 ,0.0001
Smoking status, n (%) 69 (49.3) 185 (37.3) 91 (35.7) 0.01 0.69
Hypertension, n (%) 113 (81.3) 352 (71.0) 98 (38.0) ,0.0001 ,0.0001
Center, n (%) ,0.0001 ,0.0001
US (Yale) 100 (71.4) 347 (69.8) 69 (25.1)
Hungary 28 (20.0) 86 (17.3) 111 (40.4)
Greece 12 (8.6) 64 (12.9) 95 (34.6)
*P value for Dissection cases vs. controls;
{P value for Non-dissecting aneurysm cases vs. controls.
Data presented as mean 6 standard deviation for age and as a number (%) of subjects for other variables.
P values are from Fisher exact test, except those for age, which are from the Wilcoxon rank sum test.
doi:10.1371/journal.pone.0091437.t001
Table 2. Association of two SNPs in FBN-1 with Thoracic Aortic Dissection.
Unadjusted Adjusted* Adjusted{
Genotype Case Control OR 95%CI p Value OR 95%CI p Value OR 95%CI p Value
rs2118181
CC 4 5 1.87 0.49–7.11 0.3605 1.12 0.26–4.81 0.8840 2.36 0.40–13.96 0.3441
CT 46 60 1.79 1.13–2.83 0.0125 1.82 1.11–2.99 0.0172 1.84 1.06–3.19 0.0314
CC + CT 50 65 1.80 1.15–2.80 0.0097 1.76 1.09–2.85 0.0211 1.87 1.09–3.20 0.0235
TT 90 210 Ref Ref Ref
Additive 1.64 1.11–2.42 0.0130 1.56 1.02–2.38 0.0425 1.74 1.07–2.82 0.0254
rs10519177
GG 14 21 1.39 0.67–2.89 0.3793 1.07 0.49–2.33 0.8652 1.47 0.59–3.68 0.4091
AG 54 104 1.08 0.70–1.67 0.7218 1.04 0.65–1.66 0.8685 0.86 0.52–1.43 0.5581
GG + AG 68 125 1.13 0.75–1.70 0.5473 1.05 0.68–1.62 0.8365 0.94 0.58–1.53 0.8060
AA 72 150 Ref Ref Ref
Additive 1.14 0.83–1.56 0.4122 1.04 0.74–1.45 0.8233 1.04 0.72–1.52 0.8273
*Adjusted for sex and study center.
{Adjusted for sex, study center, age, hypertension, and smoking.
doi:10.1371/journal.pone.0091437.t002
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Genotyping and Laboratory Measurements
Genotypes for individual DNA samples were determined by real
time kinetic polymerase chain reaction (PCR) as described
previously [16].
Statistical Analysis
Differences in traditional risk factors between TAD cases and
controls, or between TAA cases and controls, were assessed by the
Fisher exact test or the Wilcoxon rank sum test for discrete and
continuous characteristics, respectively. An exact test was used to
assess deviation of FBN-1 genotype frequencies from Hardy-
Weinberg expectations. The association of FBN-1 risk genotypes
with TAAD was assessed using logistic regression models: an
unadjusted model, a model adjusted for sex and study center and
that adjusted for sex, study center, age, hypertension, and
smoking. Multinomial logistic regression was applied to compute
odds ratios (OR), 95% confidence intervals (CI), and p-values for
association between the risk genotypes or risk variant carrier status
with either TAD or non-dissecting TAA versus controls.
All probability values are 2-sided and 95% confidence intervals
(CI) are presented. All analyses were performed using SAS version
9.2.
Results
Subject Characteristics, Power, and Allele Frequencies of
the FBN-1 SNPs
The characteristics of TAD and TAA cases and controls are
presented in Table 1. As might be expected, traditional risk factors
Table 3. Association of two SNPs in FBN-1 with Non-dissecting Thoracic Aortic Aneurysm.
Unadjusted Adjusted* Adjusted{
Genotype Case Control OR 95%CI p Value OR 95%CI p Value OR 95%CI p Value
rs2118181
CC 12 5 1.42 0.49–4.09 0.5159 0.80 0.24–2.70 0.7238 1.70 0.36–8.08 0.5045
CT 127 60 1.25 0.88–1.78 0.2097 1.25 0.84–1.87 0.2765 1.32 0.83–2.08 0.2421
CC + CT 139 65 1.27 0.90–1.78 0.1758 1.21 0.82–1.79 0.3361 1.34 0.86–2.09 0.2030
TT 355 210 Ref Ref Ref
Additive 1.23 0.91–1.68 0.1713 1.15 0.81–1.64 0.4380 1.32 0.88–1.98 0.1869
rs10519177
GG 42 21 1.15 0.66–2.02 0.6171 0.88 0.47–1.64 0.6869 1.25 0.59–2.69 0.5614
AG 192 104 1.07 0.78–1.46 0.6920 1.02 0.72–1.46 0.9010 0.88 0.59–1.32 0.5310
GG + AG 234 125 1.08 0.80–1.45 0.6102 1.00 0.71–1.40 0.9775 0.93 0.64–1.37 0.7154
AA 260 150 Ref Ref Ref
Additive 1.07 0.85–1.35 0.5657 0.97 0.75–1.26 0.8315 1.00 0.74–1.35 0.9914
*Adjusted for sex and study center.
{Adjusted for sex, study center, age, hypertension, and smoking.
doi:10.1371/journal.pone.0091437.t003
Table 4. Association of the SNPs in FBN-1 with Thoracic Aortic Dissection or Aneurysm.
Unadjusted Adjusted* Adjusted{
Genotype Case Control OR 95%CI p Value OR 95%CI p Value OR 95%CI p Value
rs2118181
CC 16 5 1.51 0.55–4.18 0.4273 0.87 0.27–2.81 0.8112 1.83 0.39–8.47 0.4430
CT 173 60 1.36 0.97–1.91 0.0728 1.37 0.93–2.01 0.1131 1.42 0.91–2.23 0.1229
CC + CT 189 65 1.37 0.99–1.90 0.0573 1.32 0.91–1.93 0.1439 1.45 0.93–2.24 0.0982
TT 445 210 Ref Ref Ref
Additive 1.32 0.99–1.77 0.0611 1.24 0.88–1.74 0.2227 1.41 0.94–2.10 0.0947
rs10519177
GG 56 21 1.21 0.70–2.06 0.4967 0.92 0.51–1.68 0.7919 1.30 0.62–2.75 0.4914
AG 246 104 1.07 0.79–1.44 0.6638 1.03 0.73–1.45 0.8800 0.88 0.59–1.30 0.5195
GG + AG 302 125 1.09 0.82–1.45 0.5454 1.01 0.73–1.40 0.9661 0.94 0.65–1.36 0.7350
AA 332 150 Ref Ref Ref
Additive 1.09 0.87–1.35 0.4689 0.99 0.77–1.27 0.9209 1.01 0.76–1.36 0.9317
*Adjusted for sex and study center.
{Adjusted for sex, study center, age, hypertension, and smoking.
doi:10.1371/journal.pone.0091437.t004
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such as older age, hypertension, and male gender were signifi-
cantly more prevalent among cases. The smoking status differed
between TAD cases and controls but not between TAA cases and
controls.
Based on the observed allele frequency and risk estimates from
LeMaire et al, and given the Yale Study sample size, the power to
detect FBN-1 variants association in the Yale study was .92% for
rs2118181 and .82% for rs10519177.
The minor allele frequency in controls was 12.7% for rs2118181
and 26.5% for rs10519177 which were essentially identical to
those observed by LeMaire et al (13% and 27%, respectively).
Among controls, the rs2118181 genotype frequencies were 1.8%
for CC, 21.8% for CT, 76.4% for TT, and 23.6% for carriers of
the C variant; the rs10519177 genotype frequencies were 7.6% for
GG, 37.8% for GA, 54.6% for AA, and 45.5% for carriers of the
G variant. The genotype distribution of FBN-1 variants among
controls did not deviate from Hardy-Weinberg equilibrium
expectations (p.0.64).
Association of FBN-1 SNPs with TAD TAA or TAAD in the
Yale Study
Carriers of the rs2118181 risk variant (C allele) were at
increased risk for TAD, compared with noncarriers: the odds ratio
(OR) was 1.80 (95% Confidence Interval (CI) 1.15–2.80) (Table 2).
Since the majority of cases were from the US (Yale University) and
the majority of controls were from Hungary and Greece, and since
about 23% of controls were spouses of the TAAD patients, there
was a potential for confounding in this study by study center and
sex. However, risk estimate for association of rs2118181 with TAD
was essentially unchanged after adjusting for study center and sex:
OR was 1.76, 95% CI 1.09–2.85 (Table 2). After further adjusting
for age, hypertension, and smoking, the ORs for the risk of TAAD
in rs2118181 risk carriers compared with noncarriers was 1.87
(95% CI 1.09–3.20) (Table 2). rs10519177 was not associated with
TAD either before or after adjustment (Table 2). Neither SNP was
associated with TAA, either descending or ascending TAA, or
TAAD (Table 3, Table 4, and Table S1 in File S1 and Table S2 in
File S1). Since the samples were collected in three different centers,
we reported risk estimates and genotype counts for association of
rs2118181 and rs10519177 with TAAD according to the study
center (Table S3 in File S1).
Aortic size is a risk factor for TAD and could also potentially
confound the observed association between rs2118181 FBN-1
SNPs and TAD. Since we could not adjust the association of the
SNPs with TAD by aortic size because aortic size was not available
for aneurysm-free controls, we investigated the association
between rs2118181 and aortic size among TAD cases. We did
not find significant differences in aortic size according to
rs2118181 risk variant carrier status: mean aortic size was 5.56
(95% CI: 5.37–5.73) for risk variant carriers (CC+CT) and was
5.48 (95% CI: 5.36–5.61) for noncarriers (TT) (p = 0.56).
Discussion
We found that the FBN-1 rs2118181 risk variant (C), a variant
that has been previously reported to be associated with TAD in a
GWAS conducted by LeMaire et al. [14] is also associated with
TAD in the Yale Study: carriers of the rs2118181 risk variant were
at 76% greater risk for TAD than non-carriers. The effect size for
this association remained essentially unchanged after adjusting for
potential confounders: sex, age, study center and hypertension.
This association of the FBN-1 rs2118181 risk variant with TAD
was also unlikely to be confounded by aortic size because
rs2118181 variant was not associated with aortic size among
TAD cases. In contrast, another FBN-1 risk variant, rs10519177,
was not associated with TAD in the Yale study. Neither rs2118181
nor rs10519177 were associated with either non-dissecting TAA or
TAAD in the Yale study. However, given the strong and consistent
association of rs10519177 observed in the LeMaire et al. studies,
the negative finding for this SNP in the current study could be due
to the play of chance and should be further investigated.
Interestingly, LeMaire et al, also observed a stronger association
of the FBN-1 rs2118181 risk variant with TAD than with non-
dissecting thoracic aortic aneurysm [14].
We and others have previously proposed aortic size criteria for
surgical intervention for TAD [17]. These criteria permit
extirpation of the abnormal thoracic aorta before rupture and/
or dissection are likely to occur. However, some TAD events occur
before these size criteria are met [7,18–19]. Adding the FBN-1 risk
variant may provide an opportunity to enhance our TAD risk
predictive models that currently include aortic size and other
clinical risk factors. by identifying among patients with moderately
large aneurysm those who are at greater risk for TAD due to the
presence of the FBN-1 risk variant.
There are some limitations of this study. This genetic study had
a case-control design and therefore the subjects who died of
thoracic aortic dissection or non-dissecting aneurysm rupture
could not be included in the analysis. The absence of fatal cases in
case-control studies can have a substantial negative impact on the
association results [20]. Because the case-control study design
precluded obtaining follow-up information on controls, it is
possible that some controls may experience thoracic aortic
dissection or non-dissecting aneurysm rupture later in life.
However, since thoracic aortic dissection or non-dissecting
aneurysm is relatively rare, the number of misclassified controls
is likely to be small. Matching controls were not collected for all
subjects and thus the matching could not be fully exploited in
analyses. In addition, the control group recruited at Yale
University was heterogeneous and smaller than the case group.
Because there were only a few non-Caucasian participants in this
study, we analyzed only Caucasians; therefore, the association of
the FBN-1 risk variants with TAD, TAA, and TAAD should be
further investigated in studies that would include other ethnic
groups.
Conclusions
In the multicenter case-control Yale Study, FBN-1 rs2118181
was associated with TAD but not with TAA or TAAD;
rs10519177 was not associated with TAD, TAA, or TAAD. The
negative finding for the rs10519177 SNP in the current study
could be due to chance and should be further investigated. Thus,
the study reported herein provided further support for the
association of the FBN-1 rs2118181 SNP with TAD.
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